New lantibiotic acts specifically against Corynebacteria - groundbreaking research publishes in Isme

New lantibiotic acts specifically against Corynebacteria - groundbreaking research publishes in Isme

lantibiotics produced by staphylococci are promising hopes of hope in the fight against antibiotic resistance. These antimicrobial peptides work specifically against certain organism groups without affecting the entire bacterial flora. Epilancin A37, such a lantibiotic, is specifically formed by staphylococci to combat its main competitors, the cory nerbacteria.

The research results published in the multidisciplinary journal ISME show that epilancin A37 has a special mechanism of action. This mechanism enables the lantibiotics to penetrate into the cells of the cory nerbacteria, to attack them from the inside and ultimately to kill them.

staphylococci and cory nerbacteria are important components of the microbiota in nose and skin. Research suggests that the competitive pressure between these types of bacteria favors the production of epilancin A37 by staphylococci. These findings could lead to lantibiotics such as Epilancin A37 used more specifically in the future to specifically combat certain bacteria without affecting the entire microbiota.

The study emphasizes the importance of specific mechanisms of action in the development of new antibacterial substances. The researchers at the Institute for Pharmaceutical Microbiology at the University of Bonn at the University Hospital Bonn have made an important contribution to how lantibiotics such as Epilancin A37 can be specifically used against certain bacteria.